

# Guochun Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1196814/publications.pdf>

Version: 2024-02-01

64  
papers

1,756  
citations

331670

21  
h-index

302126

39  
g-index

68  
all docs

68  
docs citations

68  
times ranked

1896  
citing authors

#	ARTICLE	IF	CITATIONS
1	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 30-39.	0.9	183
2	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , 2020, 30, 70-92.	0.6	148
3	Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2017, 19, 259.	3.5	134
4	Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies. <i>Journal of Rheumatology</i> , 2017, 44, 1051-1057.	2.0	123
5	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	5.8	105
6	Factors Predicting Malignancy in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e94128.	2.5	96
7	Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies. <i>PLoS ONE</i> , 2015, 10, e0141616.	2.5	66
8	Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. <i>Scientific Reports</i> , 2017, 7, 188.	3.3	65
9	The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2019, 10, 159.	4.8	61
10	Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. <i>Rheumatology</i> , 2020, 59, 2829-2837.	1.9	59
11	The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. <i>Clinical Rheumatology</i> , 2015, 34, 2097-2103.	2.2	47
12	The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. <i>Clinical Rheumatology</i> , 2019, 38, 2171-2179.	2.2	41
13	Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. <i>American Journal of the Medical Sciences</i> , 2018, 355, 48-53.	1.1	33
14	Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. <i>Clinical Rheumatology</i> , 2019, 38, 1655-1663.	2.2	32
15	The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. <i>Current Opinion in Rheumatology</i> , 2019, 31, 643-649.	4.3	32
16	Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis. <i>Modern Rheumatology</i> , 2017, 27, 122-129.	1.8	30
17	Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. <i>Scientific Reports</i> , 2016, 6, 27479.	3.3	29
18	Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. <i>Clinical Rheumatology</i> , 2021, 40, 2311-2317.	2.2	28

#	ARTICLE	IF	CITATIONS
19	Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2018, 45, 835-840.	2.0	23
20	Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 845988.	4.8	23
21	Discovery of new biomarkers of idiopathic inflammatory myopathy. <i>Clinica Chimica Acta</i> , 2015, 444, 117-125.	1.1	22
22	Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study. <i>Clinical Rheumatology</i> , 2018, 37, 597-605.	2.2	21
23	HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease. <i>PLoS ONE</i> , 2016, 11, e0161436.	2.5	21
24	Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center. <i>Respiratory Medicine</i> , 2019, 155, 127-132.	2.9	17
25	The RIG-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis. <i>Arthritis Research and Therapy</i> , 2019, 21, 131.	3.5	17
26	The impact of rheumatoid arthritis on work capacity in Chinese patients: a cross-sectional study. <i>Rheumatology</i> , 2015, 54, 1478-1487.	1.9	16
27	Disability and health-related quality of life in Chinese patients with rheumatoid arthritis: A cross-sectional study. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1709-1715.	1.9	16
28	The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 635654.	3.5	16
29	Muscle pathological features and extra-muscle involvement in idiopathic inflammatory myopathies with anti-mitochondrial antibody. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 741-748.	3.4	16
30	The performance of MRI in detecting subarticular bone erosion of sacroiliac joint in patients with spondyloarthropathy: A comparison with X-ray and CT. <i>European Journal of Radiology</i> , 2014, 83, 2058-2064.	2.6	14
31	Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	2.2	14
32	Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome. <i>Clinical Rheumatology</i> , 2020, 39, 2417-2424.	2.2	14
33	Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis. <i>Arthritis Research and Therapy</i> , 2021, 23, 15.	3.5	14
34	Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study. <i>Clinical Rheumatology</i> , 2019, 38, 1047-1054.	2.2	13
35	Efficacy and Safety of Loxoprofen Hydrogel Transdermal Patch Versus Loxoprofen Tablet in Chinese Patients with Myalgia: A Double-Blind, Double-Dummy, Parallel-Group, Randomized, Controlled, Non-Inferiority Trial. <i>Clinical Drug Investigation</i> , 2019, 39, 369-377.	2.2	12
36	The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial. <i>Clinical Rheumatology</i> , 2019, 38, 657-664.	2.2	12

#	ARTICLE	IF	CITATIONS
37	Plasma exosomal RNAs have potential as both clinical biomarkers and therapeutic targets of dermatomyositis. <i>Rheumatology</i> , 2022, 61, 2672-2681.	1.9	12
38	Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232096841.	2.5	11
39	Comparison of three classification criteria of rheumatoid arthritis in an inception early arthritis cohort. <i>Clinical Rheumatology</i> , 2016, 35, 2397-2401.	2.2	10
40	Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-217096.	0.9	10
41	Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies. <i>BMC Pulmonary Medicine</i> , 2022, 22, 14.	2.0	9
42	Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 174.	1.9	8
43	Clinical features, treatments and outcomes of calcinosis in adult patients with dermatomyositis: a single cohort study. <i>Rheumatology</i> , 2021, 60, 2958-2962.	1.9	7
44	Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 252-260.	1.9	6
45	Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients. <i>Clinical Rheumatology</i> , 2019, 38, 1425-1431.	2.2	6
46	The effects of infliximab in treating idiopathic inflammatory myopathies: A review article. <i>Dermatologic Therapy</i> , 2021, 34, e14976.	1.7	6
47	Interstitial Lung Disease Is a Major Characteristic of Patients Who Test Positive for Anti-PM/Scl Antibody. <i>Frontiers in Medicine</i> , 2021, 8, 778211.	2.6	6
48	Evaluation of 12 different assays for detecting ANCA in Chinese patients with GPA and MPA: a multicenter study in China. <i>Clinical Rheumatology</i> , 2019, 38, 3477-3483.	2.2	5
49	Autoantibodies: Pathogenic or epiphenomenon. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, , 101767.	3.3	5
50	Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity. <i>Mediators of Inflammation</i> , 2020, 2020, 1-8.	3.0	4
51	Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 732-741.	0.8	4
52	Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. <i>RMD Open</i> , 2022, 8, e001669.	3.8	4
53	Serum levels of anti-transcriptional intermediary factor 1- $\beta$ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152011.	3.4	4
54	Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110069.	2.7	3

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial. <i>Rheumatology and Therapy</i> , 2021, 8, 361-374.	2.3	3
56	Characterization of genotype-phenotype correlation with MORC2 mutated Axonal Charcot-Marie-Tooth disease in a cohort of Chinese patients. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 244.	2.7	3
57	Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 227-234.	0.8	3
58	Response to Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria™ by Cavagna et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-212382.	0.9	2
59	Pituitary dysfunction in patients with ANCA associated vasculitis: prevalence, presentation, and outcomes. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232093063.	2.5	2
60	Clinical heterogeneities and prognoses of patients with myositis specific antibody negative dermatomyositis: a retrospective study in China. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 284-291.	0.8	2
61	Resistin Expression Is Associated With Interstitial Lung Disease in Dermatomyositis. <i>Frontiers in Medicine</i> , 2022, 9, 903887.	2.6	2
62	miR-18a-3p and Its Target Protein HuR May Regulate Myogenic Differentiation in Immune-Mediated Necrotizing Myopathy. <i>Frontiers in Immunology</i> , 2021, 12, 780237.	4.8	1
63	Validation of new classification criteria of rheumatoid arthritis in an international multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 841-847.	0.8	1
64	Clinical heterogeneities and prognoses of patients with myositis specific antibody negative dermatomyositis: a retrospective study in China. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0